PERSANTINE

LOE Approaching

dipyridamole

NDAORALTABLET
Approved
Dec 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
14

Clinical Trials (5)

NCT00808314Phase 4Unknown

Lexiscan(TM) Rb-82 Myocardial Perfusion PET: A Comparison With Dipyridamole Stress

Started Dec 2008
32 enrolled
Coronary Artery Disease
NCT00760708N/ATerminated

Circulating Adenosine Levels Before and After Intravenous (IV) Persantine

Started Sep 2005
221 enrolled
IschemiaCoronary Disease
NCT02262793Phase 1Completed

Relative Bioavailability of Telmisartan and Dipyridamole After Co-administration Compared to the Bioavailability of Telmisartan or Dipyridamole Alone in Healthy Female and Male Subjects

Started May 2004
24 enrolled
Healthy
NCT00129038Phase 4Completed

Modified-release Dipyridamole/Aspirin (200mg/25mg bd) Versus Aspirin (75mg) in Aspirin-resistant Patients

Started Apr 2004
11 enrolled
Coronary Arteriosclerosis
NCT02273557Phase 1Completed

Bioavailability of Dipyridamole of Asasantin p.o. in Three Experimental Formulations Relative to the Standard Formulation in Healthy Male Subjects

Started Jan 2003
19 enrolled
Healthy